Evan L Brittain1, David R Janz2, Eric D Austin3, Julie A Bastarache2, Lisa A Wheeler2, Lorraine B Ware2, Anna R Hemnes2. 1. Division of Cardiovascular Medicine, Vanderbilt University Medical School, Nashville, TN. Electronic address: evan.brittain@vanderbilt.edu. 2. Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical School, Nashville, TN. 3. Department of Pediatrics, Vanderbilt University Medical School, Nashville, TN.
Abstract
BACKGROUND: Cell-free hemoglobin (CFH) is a potent nitric oxide scavenger associated with poor outcomes in several diseases. Pulmonary arterial hypertension (PAH) is characterized by reduced nitric oxide availability. We hypothesized that CFH would be elevated in PAH and would associate with hemodynamics and clinical outcomes. METHODS: We measured CFH in 200 consecutively evaluated patients with PAH, 16 unaffected bone morphogenetic receptor protein type 2 (BMPR2) mutation carriers, 19 healthy subjects, and 29 patients with pulmonary venous hypertension (PVH). CFH values were tested for association with hemodynamics, time to hospitalization, and death. RESULTS: CFH was elevated in patients with PAH and BMPR2 carriers compared with healthy subjects and patients with PVH (P ≤ .01 all comparisons). There were no differences in CFH across PAH subtypes. CFH modestly correlated with mean pulmonary artery pressure (ρ = 0.16, P = .03) and pulmonary vascular resistance (ρ = 0.21, P = .01) and inversely with cardiac index (ρ = -0.18, P = .02) in patients with PAH. CFH was not associated with hemodynamic response to nitric oxide or death. Patients with the highest CFH levels had increased risk of PAH-related hospitalization when adjusted for age, sex, and PAH cause (hazard ratio, 1.69; 95% CI ,1.08-2.66; P = .02). CONCLUSIONS: CFH is elevated in patients with PAH and BMPR2 carriers compared with healthy subjects and patients with PVH. Elevated CFH levels are independently associated with an increased risk of hospitalization. Further study is required to understand the mechanism of CFH elevation and the potential pathologic contribution of CFH in PAH.
BACKGROUND: Cell-free hemoglobin (CFH) is a potent nitric oxide scavenger associated with poor outcomes in several diseases. Pulmonary arterial hypertension (PAH) is characterized by reduced nitric oxide availability. We hypothesized that CFH would be elevated in PAH and would associate with hemodynamics and clinical outcomes. METHODS: We measured CFH in 200 consecutively evaluated patients with PAH, 16 unaffected bone morphogenetic receptor protein type 2 (BMPR2) mutation carriers, 19 healthy subjects, and 29 patients with pulmonary venous hypertension (PVH). CFH values were tested for association with hemodynamics, time to hospitalization, and death. RESULTS:CFH was elevated in patients with PAH and BMPR2 carriers compared with healthy subjects and patients with PVH (P ≤ .01 all comparisons). There were no differences in CFH across PAH subtypes. CFH modestly correlated with mean pulmonary artery pressure (ρ = 0.16, P = .03) and pulmonary vascular resistance (ρ = 0.21, P = .01) and inversely with cardiac index (ρ = -0.18, P = .02) in patients with PAH. CFH was not associated with hemodynamic response to nitric oxide or death. Patients with the highest CFH levels had increased risk of PAH-related hospitalization when adjusted for age, sex, and PAH cause (hazard ratio, 1.69; 95% CI ,1.08-2.66; P = .02). CONCLUSIONS:CFH is elevated in patients with PAH and BMPR2 carriers compared with healthy subjects and patients with PVH. Elevated CFH levels are independently associated with an increased risk of hospitalization. Further study is required to understand the mechanism of CFH elevation and the potential pathologic contribution of CFH in PAH.
Authors: Paul W Buehler; Jin Hyen Baek; Christina Lisk; Ian Connor; Tim Sullivan; Douglas Kominsky; Susan Majka; Kurt R Stenmark; Eva Nozik-Grayck; Joe Bonaventura; David C Irwin Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-06-22 Impact factor: 5.464
Authors: Peter C Minneci; Katherine J Deans; Huang Zhi; Peter S T Yuen; Robert A Star; Steven M Banks; Alan N Schechter; Charles Natanson; Mark T Gladwin; Steven B Solomon Journal: J Clin Invest Date: 2005-11-17 Impact factor: 14.808
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245
Authors: Ivan M Robbins; Anna R Hemnes; Meredith E Pugh; Evan L Brittain; David X Zhao; Robert N Piana; Pete P Fong; John H Newman Journal: Circ Heart Fail Date: 2013-12-02 Impact factor: 8.790
Authors: David R Janz; Julie A Bastarache; Josh F Peterson; Gillian Sills; Nancy Wickersham; Addison K May; L Jackson Roberts; Lorraine B Ware Journal: Crit Care Med Date: 2013-03 Impact factor: 7.598
Authors: Emma K Larkin; John H Newman; Eric D Austin; Anna R Hemnes; Lisa Wheeler; Ivan M Robbins; James D West; John A Phillips; Rizwan Hamid; James E Loyd Journal: Am J Respir Crit Care Med Date: 2012-08-23 Impact factor: 21.405
Authors: Olga Rafikova; Elissa R Williams; Matthew L McBride; Marina Zemskova; Anup Srivastava; Vineet Nair; Ankit A Desai; Paul R Langlais; Evgeny Zemskov; Marc Simon; Lawrence J Mandarino; Ruslan Rafikov Journal: Am J Respir Cell Mol Biol Date: 2018-09 Impact factor: 6.914
Authors: Roger A Alvarez; Megan P Miller; Scott A Hahn; Joseph C Galley; Eileen Bauer; Timothy Bachman; Jian Hu; John Sembrat; Dmitry Goncharov; Ana L Mora; Mauricio Rojas; Elena Goncharova; Adam C Straub Journal: Am J Respir Cell Mol Biol Date: 2017-12 Impact factor: 6.914
Authors: Ciara M Shaver; Nancy Wickersham; J Brennan McNeil; Hiromasa Nagata; Adam Miller; Stuart R Landstreet; Jamie L Kuck; Joshua M Diamond; David J Lederer; Steven M Kawut; Scott M Palmer; Keith M Wille; Ann Weinacker; Vibha N Lama; Maria M Crespo; Jonathan B Orens; Pali D Shah; Chadi A Hage; Edward Cantu; Mary K Porteous; Gundeep Dhillon; John McDyer; Julie A Bastarache; Jason D Christie; Lorraine B Ware Journal: JCI Insight Date: 2018-01-25
Authors: V Eric Kerchberger; Julie A Bastarache; Ciara M Shaver; Hiromasa Nagata; J Brennan McNeil; Stuart R Landstreet; Nathan D Putz; Wen-Kuang Yu; Jordan Jesse; Nancy E Wickersham; Tatiana N Sidorova; David R Janz; Chirag R Parikh; Edward D Siew; Lorraine B Ware Journal: JCI Insight Date: 2019-11-01
Authors: Yidan D Zhao; Lei Chu; Kathleen Lin; Elise Granton; Li Yin; Jenny Peng; Michael Hsin; Licun Wu; Amy Yu; Thomas Waddell; Shaf Keshavjee; John Granton; Marc de Perrot Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240